Authors:

Sumithra Urs, Steven Jones, Joshua Mandella, Mary Anne Meade, Kevin Guley, Sarah Krueger, Alden Wong, David Draper, Scott Wise, Dylan Daniel, and Maryland Rosenfeld Franklin

Year:

2018

World Preclinical Congress

Poster: Rational Combinations of Immunotherapy Agents with Targeted Radiation in Murine Breast Cancer Models

Poster: Rational Combinations of Immunotherapy Agents with Targeted Radiation in Murine Breast Cancer Models

Introduction and Background

  • Breast cancer is regarded as an immunologically “cold” cancer, often with minimal CD8+ T cell infiltration and a low mutational burden.
  • In the preclinical space, there is need for robust and representative breast cancer models to test immuno-oncology (I/O) combination strategies that may convert “non-responders” (cold) to “responders” (hot) or “warm responders.”
  • Radiation therapy (RT) is a clinical treatment modality utilized in breast cancer and is known to modify the tumor microenvironment, induce cytokines, and chemokines, and has been shown to potentially synergize with immunotherapies.
  • RT alone is insufficient to induce curative anti-tumor immune response especially in metastatic cancer, highlighting the need for combination immunotherapy strategies to boost the immune system.
  • We have characterized the tumor immune profile of three breast cancer models, 4T1, EMT6 and E0771; and their response to focal radiation, costimulatory agonists, and checkpoint inhibitors in pharmacology efficacy studies.
  • RT combination with immunomodulatory agents are shown and the data aims at understanding the effects of tumor response which can be used for rational design of combination strategies.